Efficacy of microcin J25 in biomatrices and in a mouse model of Salmonella infection

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 4, 2007, Pages 676-680

  Lopez, Fabian E ^a   Vincent, Paula A ^a   Zenoff, Ana M ^a   Salomón, Raúl A ^a   Farías, Ricardo N ^a  

^a UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

Antimicrobial peptides; In vivo activity; Stability in biomatrices

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; MICROCIN J25; RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIOCIN; MICROCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL SALMONELLOSIS; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BLOOD; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; EX VIVO STUDY; HEMOLYSIS; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIVER; MOUSE; NONHUMAN; PLASMA; QUANTITATIVE ASSAY; SERUM; SINGLE DRUG DOSE; SPLEEN; ANIMAL; DRUG EFFECT; HALF LIFE TIME; HUMAN; MICROBIOLOGY; SALMONELLOSIS;

AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOCINS; COLONY COUNT, MICROBIAL; HALF-LIFE; HEMOLYSIS; HUMANS; LIVER; MICE; SALMONELLA INFECTIONS; SPLEEN;

EID: 34250017796     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm009     Document Type: Article

References (19)

1. Salomón RA, Farías RN. Microcin 25, a novel antimicrobial peptide produced by Escherichia coli. J Bacteriol 1992; 174: 7428-35.
2. Vincent PA, Delgado MA, Farias RN et al. Inhibition of Salmonella enterica serovars by microcin J25. FEMS Microbiol Lett 2004; 236: 103-7.
3. Bayro MJ, Mukhopadhyay J, Swapna GV et al. Structure of antibacterial peptide microcin J25: A 21-residue lariat protoknot. J Am Chem Soc 2003; 125: 12382-3.
4. Rosengren KJ, Clark RJ, Daly NL et al. Microcin J25 has a threaded sidechain-to-backbone ring structure and not a head-to-tail cyclized backbone. J Am Chem 2003; 125: 12464-74.
5. Wilson KA, Kalkum M, Ottesen J. et al. Structure of microcin J25, a peptide inhibitor of bacterial RNA polymerase, is a lassoed tail. J Am Chem Soc 2003; 125: 12475-83.
6. Rintoul MR, de Arcuri BF, Salomon RA et al. The antibacterial action of microcin J25: Evidence for disruption of cytoplasmic membrane energization in Salmonella newport. FEMS Microbiol Lett 2001; 204: 265-70.
7. Miyazaki S, Okazaki K, Tsuji M et al. Pharmacodynamics of S-3578, a novel cephem, in murine lung and systematic infection models. Antimicrob Agents Chemother 2004; 48: 378-83.
8. Khan SA, Strijbos PJLM, Everest P et al. Early responses to Salmonella typhimurium infection in mice occur at focal lesions in infected organs. Microb Pathog 2001; 30: 29-38.
9. Levy O, Elsbach P. Bactericidal/permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis. Curr Infect Dis Rep 2001; 3: 407-12.
10. Gura T. Innate immunity. Ancient system gets new respect. Science 2001; 291: 2068-71.
11. Levy O. Antimicrobial proteins and peptides of blood: Templates for novel antimicrobial agents. Blood 2000; 96: 2664-72.
12. Chen J, Falla TJ, Liu H et al. Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthetic protegrin analogues. Biopolymers 2000; 55: 88-98.
13. Ge Y, MacDonald D, Henry MM et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 1999; 35: 45-53.
14. Jeu L, Fung HB. Daptomycin: A cyclic lipopeptide antimicrobial agent. Clin Ther 2004; 26: 1728-57.
15. Craig WA, Welling PG. Protein binding of antimicrobials: Clinical pharmacokinetics and therapeutic implications. Clin Pharmacokinet 1977; 2: 252-68.
16. Dutcher BS, Reynard AM, Beck ME et al. Potentiation of antibiotic activity by normal serum. Antimicrob Agents Chemother 1978; 13 820-6.
17. Marca G, Veronese M, Petrescu D. Enhancement of the bacteriostatic and bactericidal activities of chloramphenicol and thiamphenicol by normal serum in vitro. Chemotherapy 1973; 18: 91-8.
18. Pruul H, Reynolds BL. Interaction of complement and polymyxin with Gram-negative bacteria. Infect Immun 1972; 6: 709-17.
19. Stratton CW, Reller LB. Serum dilution test for bactericidal activity. 1. Selection of a physiological diluent. J Infect Dis 1977; 136 187-94.